IP Library Granted Patent US 8,445,002
Granted Patent B2
US 8,445,002 · App. 12/742,235 · Granted May 21, 2013

Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same

Inventor: Zahra Mansouri (Tahoe City, CA)
Assignee: Laboratory Skin Care, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,445,002
App. No.
12/742,235
Granted
May 21, 2013
Kind
B2
Abstract

Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.

Claims (27)

1. A topical composition comprising uniform, rigid, spherical nanoporous calcium phosphate particles, wherein

at least 90% of the particles have a diameter of 2 microns or less;

the particles are chemically pure and are described by the formula Ca 10 (PO 4 ) 6 (OH) 2 ; and

the particles are complexed with an active agent.

2. The topical composition according to claim 1 , wherein the particles have a pore volume ranging from 30 to 85%.

3. The topical composition according to claim 2 , wherein the particles have a pore size ranging from 2 nm to 100 nm.

4. The topical composition according to claim 1 , wherein the particles are produced by:

preparing a fluid composition of calcium phosphate crystals;

spray drying the fluid composition to produce precursor particles; and

subjecting the precursor particles to an elevated temperature ranging from 300 to 800° C. for a period of time ranging from 1 hour to 10 hours to produce uniform, rigid, spherical nanoporous calcium phosphate calcium phosphate particles.

5. The topical composition according to claim 1 further comprising a topical delivery vehicle.

6. The topical composition according to claim 1 , wherein the amount of active agent complexed with the particles ranges from 0.01 to 300 mg of active agent per gram of particles.

7. The topical composition according to claim 1 , wherein the active agent is selected from the group consisting of antibiotic agents, antifungal agents, anthelmintic agents, antimalarial agents, antiprotozoal agents, cardioprotective agents, psychopharmacological agents, pharmacodynamic agents and chemotherapeutic agents.

8. The topical composition according to claim 1 , wherein the active agent is non-covalently bound to the particles.

9. A method of delivering an active agent to a subject, the method comprising applying to a topical region of the subject a composition comprising uniform, rigid, spherical nanoporous calcium phosphate particles, wherein

at least 90% of the particles have a diameter of 2 microns or less;

the particles are chemically pure and are described by the formula Ca 10 (PO 4 ) 6 (OH) 2 ; and

the particles are complexed with an active agent.

10. The method according to claim 9 , wherein the particles have a pore volume ranging from 30 to 85%.

11. The method according to claim 10 , wherein the particles have a pore size ranging from 2 nm to 100 nm.

12. The method according to claim 9 , wherein the amount of active agent complexed with the particles ranges from 0.01 to 300 mg of active agent per gram of particles.

13. The method according to claim 9 , wherein the topical region is a mucosal location.

14. The method according to claim 9 , wherein the topical region is a keratinized skin surface.

15. The method according to claim 14 , wherein the method comprises delivering the active agent at least into the stratum corneum of the subject.

16. The method according to claim 14 , wherein the method comprises delivering the active agent into the deep stratum corneum of the subject.

17. The method according to claim 14 , wherein the method comprises delivering the active agent into the dermis of the subject.

18. The method according to claim 14 , wherein the method comprises systemically delivering the active agent to the subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2011
From: MANSOURI, ZAHRA
To: LABORATORY SKIN CARE, INC.
Reel/Frame 025954/0077 →
Continuity (2)
Provisional Application 61176057 · May 6, 2009
Related Publication 20110189239A1 · Aug 4, 2011